Skip to main content

Market Overview

Neurocrine Pens $2.6B Pact With Sosei Heptares For Neuro Targets

Share:
Neurocrine Pens $2.6B Pact With Sosei Heptares For Neuro Targets

Neurocrine Biosciences Inc (NASDAQ: NBIX) has outlined a deal that provides Sosei Heptares Corporation $100 million upfront, R&D expenses, and a motherlode of milestones worth up to $2.6 billion if successful. 

  • Under the terms of the agreement, Neurocrine Biosciences gains development and commercialization rights to muscarinic receptor agonists for schizophrenia, dementia, and other neuropsychiatric disorders.
  • The most advanced program, HTL-0016878, is a selective M4 agonist. Neurocrine Biosciences plans to submit an Investigational New Drug (IND) application and initiate a Phase 2 study for schizophrenia in 2022.
  • Under the pact, Sosei Heptares retains the rights to develop M1 agonists in Japan, while Neurocrine nabs co-development and profit share options.
  • Muscarinic receptors are crucial to brain function and are researched in drug targets in psychosis and cognitive disorders.
  • Price Action: NBIX shares are down 0.66% at $85.45 during the market session on the last check Monday.
 

Related Articles (NBIX)

View Comments and Join the Discussion!

Posted-In: Briefs SchizophreniaBiotech News Health Care Contracts General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com